Chronic gastritis

disease
On this page

Also known as chronic gastritis (disease)gastritis (disease), chronic

Summary

Chronic gastritis (MONDO:0005001) is a disease and 31 clinical trials. Top therapeutic interventions include berberine, esomeprazole, and clarithromycin. A subtype of gastritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 31

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namechronic gastritis
Mondo IDMONDO:0005001
EFOEFO:0000337
NCITC26929
SNOMED CT8493009
UMLSC0085695
MedGen39089
Is cancer (heuristic)no

Also known as: chronic gastritis · chronic gastritis (disease) · gastritis (disease), chronic

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of gastritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderstomach disordergastritischronic gastritis

Related subtypes (15): gastroduodenal Crohn disease, viral gastritis, eosinophilic gastritis, bacterial gastritis, fungal gastritis, lymphocytic gastritis, necrotizing gastritis, granulomatous gastritis, gastroduodenitis, alcoholic gastritis, gastric mucosal hypertrophy, chronic erosive gastritis, autoimmune gastritis, collagenous gastritis, pediatric collagenous gastritis

Subtypes (1): chronic atrophic gastritis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
AbeprazanPhase 3 (in late-stage trials)
EsomeprazolePhase 3 (in late-stage trials)
RebamipidePhase 3 (in late-stage trials)
RecoflavonePhase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 31.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE311
PHASE49
Not specified9
PHASE21
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01119768PHASE4COMPLETEDEsomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
NCT01817556PHASE4COMPLETEDA Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.
NCT02356679PHASE4COMPLETEDEfficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients
NCT03609892PHASE4COMPLETEDHelicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
NCT04697186PHASE4COMPLETEDHelicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
NCT05014334PHASE4COMPLETEDStudy on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication
NCT06514274PHASE4COMPLETEDStudy on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication
NCT06603688PHASE4UNKNOWNStudy on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.
NCT07312721PHASE4COMPLETEDComparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis
NCT00455806PHASE3UNKNOWNEsomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection
NCT00996788PHASE3COMPLETEDAnti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis
NCT01813812PHASE3UNKNOWNA Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034
NCT02219529PHASE3COMPLETEDMagnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases
NCT02282670PHASE3UNKNOWNA Study to Evaluate the Efficacy and Safety of DA-5204
NCT03443804PHASE3COMPLETEDTo Evaluate the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients
NCT04066530PHASE3COMPLETEDA Study to Evaluate the Efficacy and Safety of AD-203
NCT04189705PHASE3COMPLETEDA Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
NCT04341454PHASE3COMPLETEDStudy to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis
NCT05163756PHASE3COMPLETEDTo Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient
NCT06151210PHASE3COMPLETEDClinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
NCT07139886PHASE2COMPLETEDA Study to Evaluate the Safety and Efficacy of DA9601 for Acute and Chronic Gastritis and to Determine the Optimal Clinical Dosage and Administration
NCT02658864PHASE1COMPLETEDPharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets
NCT04702542Not specifiedACTIVE_NOT_RECRUITINGTo Develop Methods for the Rehabilitation of Chronic Gastroduodenal Pathology in Children.
NCT05021029Not specifiedENROLLING_BY_INVITATIONUC Davis Cohort of Pre-Malignant and Malignant Gastro-Intestinal DisEases Study
NCT07129824Not specifiedNOT_YET_RECRUITINGRelationship Between Diet and Gastritis
NCT07542652Not specifiedRECRUITINGAssociation Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis
NCT03847753Not specifiedCOMPLETEDExploring the Comorbidity Between Mental Disorders and General Medical Conditions
NCT05048069Not specifiedUNKNOWNPost-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab.
NCT05073614Not specifiedCOMPLETEDEvaluation of Immunohistochemical Expression of Heparanase in Helicobacter Pylori-Associated Chronic Gastritis
NCT05666531Not specifiedUNKNOWNResearch on Innovative Diagnosis and Treatment System of Syndrome Differentiation of Zang-fu Viscera and Effectiveness Evaluation Based on Inter-Arm Blood Pressure Measured Simultaneously
NCT06269380Not specifiedCOMPLETEDEvaluation of Antral Biopsies Obtained in Normal Esophagogastroduodenoscopy

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
BERBERINE415
ESOMEPRAZOLE45
CLARITHROMYCIN44
RABEPRAZOLE42
VONOPRAZAN42
AMOXICILLIN41
FURAZOLIDONE41
MINOCYCLINE41
MOXIFLOXACIN41
TETRACYCLINE41
REBAMIPIDE35
LAFUTIDINE31
RECOFLAVONE31
METERGOLINE21
CHEMBL313767305
CHEMBL170333602
CHEMBL137473801
CHEMBL157216701